|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative expenses | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other expense: | |||||
| Interest income | |||||
| Loss on debt conversion with related party | |||||
| Loss on fixed asset disposal | |||||
| Interest income (expense), net | |||||
| Exchange loss, net | |||||
| Total other expense | |||||
| Loss before income taxes | |||||
| Deferred income tax (expense) benefit | |||||
| Net loss | |||||
| Foreign currency translation adjustment | |||||
| Comprehensive loss | |||||
| Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per common share, basic (in dollars per share) | |||||
| Net loss per common share, diluted (in dollars per share) | |||||
| Weighted average number of shares outstanding - basic (in shares) | |||||
| Weighted average number of shares outstanding - diluted (in shares) | |||||
Loading...